{
  "nctId": "NCT04946552",
  "briefTitle": "Sympathetic Activation in Obesity",
  "officialTitle": "Sympathetic Activation in Obesity",
  "protocolDocument": {
    "nctId": "NCT04946552",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2022-03-30",
    "uploadDate": "2023-09-28T17:54",
    "size": 1119050,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04946552/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 5,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-11-23",
    "completionDate": "2022-09-30",
    "primaryCompletionDate": "2022-09-30",
    "firstSubmitDate": "2021-06-15",
    "firstPostDate": "2021-07-01"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Age 18-45 years\n4. In good general health as evidenced by medical history and lean (BMI 18.5-24.9 kg/m2) or non-diabetic obese (BMI 30-50 kg/m2) with a fasting plasma glucose (FPG) \\<100 mg/dL and a hemoglobin A1c \\<5.7%.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Hypertension\n2. Cardiac or pulmonary disease,\n3. Known history of Type 1 or Type 2 diabetes\n4. Hepatic disease, swallowing and gastrointestinal disorders\n5. Current use of anti-obesity medications, supplements and/or anti-hyperglycemic medications\n6. Neurological injury or illness, and psychiatric medications\n7. Women who are pregnant or lactating\n8. Subjects who suffer from claustrophobia\n9. Subjects who have received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to participation in this study\n10. Radiation works or participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits.\n11. Subjects with history of IV drug use which would prevent venous access for PET tracer injection\n12. Severe motor problems that prevent the subject from lying still for PET and MR imaging\n13. Subjects who complain of chronic pain\n14. Blood donation within 8 weeks of the study",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "45 Years",
    "stdAges": [
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System",
        "description": "Lean individuals with a BMI of 18-25 and obese individuals with a BMI of 30-40 will undergo a PET/CT scan to determine group differences in sympathetic nervous system (SNS) activity in white adipose tissue (WAT), brown adipose tissue (BAT), and deltoid muscle. SNS activity will be determined by using \\[11C\\]MRB a radiotracer for PET imaging.",
        "timeFrame": "120 minutes"
      },
      {
        "measure": "Microneurography (Muscle Sympathetic Nerve Activity (MSNA)) Measured by Burst Frequency",
        "description": "Muscle sympathetic nerve activity will be quantified by identification and measurement of sympathetic bursts in the integrated neurogram and expressed as burst frequency (mean number of bursts per unit time) to determinate group differences in peroneal MSNA at baseline (fasting) and during MMT.",
        "timeFrame": "30-60 minutes"
      }
    ],
    "secondary": [
      {
        "measure": "DVR of Norepinephrine Transporter (NET) in the Central Nervous System (CNS)",
        "description": "Regional quantification of \\[11C\\]MRB uptake as distribution volume ratio (DVR ) will be used to measure NET in the CNS.",
        "timeFrame": "120 minutes"
      },
      {
        "measure": "DVR of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System After Mixed Meal Test",
        "description": "Measurement of peripheral SNS Activity with \\[11C\\]MRC for PET/CT before (fasting) and after a high carbohydrate mixed meal in individuals with normal weight and obesity.",
        "timeFrame": "120 minutes"
      },
      {
        "measure": "Plasma Glucose",
        "description": "Measurement of plasma glucose levels will be obtained at fasting and during the Mixed Meal Test (MMT). The normal range for glucose levels is 70-100 mg/dL.",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Insulin Levels",
        "description": "Measurement of plasma insulin levels will be obtained at fasting and during the MMT. Insulin levels in the plasma are higher in individuals with obesity. The normal range for insulin is: \\< or = 19.6 mcg/dL",
        "timeFrame": "2 hours"
      },
      {
        "measure": "C-Peptide",
        "description": "Plasma samples will be drawn at baseline and throughout the MMT for measurement of C-Peptide. The normal range for C-Peptide is 0.80 - 3.85 ng/mL",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Plasma Catecholamines (Epinephrine and Norepinephrine)",
        "description": "Measurement of epinephrine and norepinephrine levels in the plasma at fasting and during the MMT. The normal range for epinephrine is 0 to 140 pg/mL (764.3 pmol/L). The normal range for norepinephrine is 70 to 1700 pg/mL (413.8 to 10048.7 pmol/L).",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Plasma Free Fatty Acids (FFA)",
        "description": "Percent of plasma free fatty acids levels will be obtained at fasting and during the Mixed Meal Test (MMT). FFA levels in the plasma are higher in individuals with obesity than individuals with normal weight.",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Thyroid Function Tests",
        "description": "Plasma samples will be drawn at baseline and throughout the mixed meal test (MMT) for measurement of Thyroid Stimulating Hormone (TSH), free T4 (FT4) and total T3 (TT3). The normal range for TSH is : 0.4-4.5 mlU/L, FT4: 0.8-1.8 ng/dL, TT3: 76 - 181 ng/dL.",
        "timeFrame": "2 hours"
      },
      {
        "measure": "Electrocardiogram (EKG)- Heart Rate",
        "description": "EKG surface electrodes will be applied to the chest for measurement of heart rate and heart rate variability (QT Interval).",
        "timeFrame": "30-60 minutes"
      },
      {
        "measure": "Electrocardiogram (EKG) - RR Interval",
        "description": "EKG surface electrodes will be applied to the chest for measurement of RR interval.",
        "timeFrame": "30-60 minutes"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 10,
      "otherCount": 0,
      "totalCount": 12
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 74,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:16.422Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}